← All indications
Tendinopathy
Clinical syndrome describing overuse tendon injuries characterized by a combination of PAIN, diffuse or localized swelling, and impaired performance.
Subtype terms (5)
More specific conditions that are subtypes of Tendinopathy in the MeSH hierarchy.
- Elbow Tendinopathy
5 drugs (2 approved, 3 experimental)
- Enthesopathy
- Giant Cell Tumor of Tendon Sheath
8 drugs (3 approved, 5 experimental)
- Tendon Entrapment
3 drugs (1 approved, 2 experimental)
- Tenosynovitis
9 drugs approved
Drugs by status
Approved for this indication (6)
Phase 4 trials (8)
Phase 3 trials (16)
Phase 2 trials (11)
Phase 1 trials (5)
Organizations
Organization Involved with Phase 4 Indications (24)
- Merck
- Zimmer Biomet
- Aarhus University
- Rockefeller University
- Azienda Ospedaliera San Giovanni Battista
- Case Western Reserve University
- Harvard University
- Fortius Clinic
- New York University
- Stanford University
- University of Bologna
- Wroclaw Medical University
- Argentine Tennis Association
- Fortius Clinic, London
- OrthoCarolina Research Institute
- Sun Yat-Sen University
- Pennsylvania State University
- University of Nantes
- Erasmus University Rotterdam
- Dutch Arthritis Association
- The Anna Foundation
- Government of Denmark
- The University of Texas, Dallas
- Sutherland Medical Center
Organization Involved with Phase 3 Indications (22)
- PPD
- Cerimon Pharmaceuticals
- Endo Pharmaceuticals
- Laboratório Teuto Brasileiro S/A
- MiMedx Group, Inc.
- United States Navy
- Brown University
- Chang Gung University
- Faculdade de Medicina do ABC
- Helse Møre og Romsdal HF
- Hospital Universitario Central de Asturias
- Laboratorio Brasileiro de Biologia
- Northwell Health
- Centre de Recherche Rhumatologique et Thermal
- University of Calgary
- Central Norway Regional Health Authority
- S.C. Corinthians Paulista
- ABC Foundation School of Medicine
- MEDRx Co., Ltd.
- Sport Science Association of Alberta
- MedStar Cardiovascular Research Network
- R3 Stem Cell
Organization Involved with Phase 2 Indications (15)
- Zars Pharma Inc.
- Ipsen
- Novartis
- Cure Therapeutics
- Kessler Foundation
- University of London
- Gottfried Wilhelm Leibniz Universität Hannover
- University of Michigan
- University of Bordeaux
- Wayne State University
- University of Versailles
- Zhejiang University
- University of Wisconsin
- Zhejiang Xingyue Biotechnology Co., Ltd.
- Unidade Local de Saúde do Alto Minho
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (18)
- InGeneron, Inc.
- Bnai Zion Medical Center
- Lakehead University
- Mansoura University
- Purdue University
- Royal College of Surgeons, Ireland
- Regeneris Medical
- GARM USA
- Emek Medical Center
- Rush University
- University of Alabama, Birmingham
- Global Alliance for Regenerative Medicine
- Health Research Board, Ireland
- Iberica Co. Ltd.
- Northern Ontario School of Medicine
- Institute of Sports Medicine, Copenhagen
- Andrews Research & Education Foundation
- Sanford Orthopedics & Sports Medicine